Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer

Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer

Nicole M Engel-Nitz,1 Mary G Johnson,1 Michael P Johnson,1 Ashley S Cha-Silva,2 Samantha K Kurosky,2 Xianchen Liu2 1Optum, Eden Prairie, MN, 55344, USA; 2Pfizer Inc, New York, NY, 10017, USACorrespondence: Nicole M Engel-Nitz, HEOR | Optum Life Sciences, MN950-1000, 11000 Optum Circle, Eden Prairie,...

Full description

Bibliographic Details
Main Authors: Engel-Nitz NM, Johnson MG, Johnson MP, Cha-Silva AS, Kurosky SK, Liu X
Format: Article
Language:English
Published: Dove Medical Press 2023-04-01
Series:Patient Preference and Adherence
Subjects:
breast cancer
palbociclib
adherence
persistence
metastatic
Online Access:https://www.dovepress.com/palbociclib-adherence-and-persistence-in-patients-with-hormone-recepto-peer-reviewed-fulltext-article-PPA

Internet

https://www.dovepress.com/palbociclib-adherence-and-persistence-in-patients-with-hormone-recepto-peer-reviewed-fulltext-article-PPA

Similar Items